Cargando…

A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells

Systemic administration of anti-programmed cell death 1 (PD-1) antibody (Ab) has achieved remarkable success in metastatic cancers. The blockade of PD-1-mediated signaling pathways sometimes cause immune-related adverse events (irAEs) due to restored anti-cancer as well as anti-self immunity. Althou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sekai, Ikue, Hagiwara, Satoru, Watanabe, Tomohiro, Kudo, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298218/ https://www.ncbi.nlm.nih.gov/pubmed/33665689 http://dx.doi.org/10.1007/s12328-020-01317-y

Ejemplares similares

Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease
por: Hagiwara, Satoru, et al.
Publicado: (2021)

Case Report: A Case of Intestinal Behçet's Disease Exhibiting Enhanced Expression of IL-6 and Forkhead Box P3 mRNA After Treatment With Infliximab
por: Yoshikawa, Keisuke, et al.
Publicado: (2021)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Case Report: Regulatory T Cell-Independent Induction of Remission in a Patient With Collagenous Colitis
por: Honjo, Hajime, et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease
por: Minaga, Kosuke, et al.
Publicado: (2020)

Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma
por: Takada, Ryutaro, et al.
Publicado: (2021)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
por: Kudo, Fumiaki, et al.
Publicado: (2018)

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
por: Masuda, Ken, et al.
Publicado: (2019)

Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis
por: Hagiwara, Satoru, et al.
Publicado: (2017)

Autoimmune hepatitis and IgG4-related disease
por: Minaga, Kosuke, et al.
Publicado: (2019)

Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
por: Higashi, Tetsuo, et al.
Publicado: (2020)

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
por: Les, Iñigo, et al.
Publicado: (2021)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
por: Kanbayashi, Yuko, et al.
Publicado: (2023)

Advances in Immunotherapy for Hepatocellular Carcinoma
por: Hagiwara, Satoru, et al.
Publicado: (2023)

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series
por: Ganta, Nagapratap, et al.
Publicado: (2022)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
por: Zhao, Xin, et al.
Publicado: (2022)

Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
por: Hara, Yoshihiro, et al.
Publicado: (2022)

Cold-inducible RNA-binding protein promotes the development of liver cancer
por: Sakurai, Toshiharu, et al.
Publicado: (2015)

Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer
por: Takada, Shinya, et al.
Publicado: (2022)

Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus
por: Kim, Soo Ki, et al.
Publicado: (2022)

Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
por: Yamauchi, Ichiro, et al.
Publicado: (2019)

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
por: Dudzińska, Marta, et al.
Publicado: (2020)

Rheumatoid Arthritis Symptoms Diagnosed by Rheumatic Immune-related Adverse Events Caused by Nivolumab in a Patient with Esophageal Cancer
por: Yasui, Sho, et al.
Publicado: (2022)

Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma
por: Minami, Yasunori, et al.
Publicado: (2023)

SUN-414 Immune Related Adverse Events: Isolated ACTH Deficiency with Nivolumab/Ipilimumab Combination Therapy
por: Magdaleno, Angela, et al.
Publicado: (2019)

Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab
por: Mizutani, Kosuke, et al.
Publicado: (2021)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Yoneda, Hiroto, et al.
Publicado: (2021)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
por: Sawada, Ryo, et al.
Publicado: (2021)

Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Hagiwara, Satoru, et al.
Publicado: (2021)

Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma
por: Sakurai, Toshiharu, et al.
Publicado: (2017)

A case of small invasive gastric cancer arising from Helicobacter pylori‐negative gastric mucosa: Fundic gland‐type adenocarcinoma
por: Komeda, Yoriaki, et al.
Publicado: (2017)

Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study
por: Washino, Satoshi, et al.
Publicado: (2021)

A case of HCC successfully treated with infliximab‐steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy
por: Hagiwara, Satoru, et al.
Publicado: (2022)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8ucior5bdbobn1jpa4nmgfap28